Dragos Damian wants to drive Terapia Ranbaxy back to growth

Dragos Damian, who returned to the CEO position at Terapia Ranbaxy drug maker last December, after having run the operations of another two major producers, Zentiva and Actavis, says his priority this year is to revert to growth after last year’s 7% decline. “The goal is to have 10% growth in 2010 against 2009 and regain lost market share. We lost between 0.5% and 0.7% of the market,” said Dragos Damian in an interview with ZF. “Overregulation has cost Terapia Ranbaxy a lot. On the other hand, in top ten Terapia Ranbaxy products we are market leaders. Maybe we haven’t focused enough on the second tier, products launched in the past three to four years. These are two main causes, but there are also others (…),” explained Damian. He says another goal for this year is to “optimise the Daiichi Sankyo hybrid model”, a model entailing the launch of products belonging to the parent company on the domestic market, through Terapia Ranbaxy. “A third goal is that the base we created for Europe should develop in Romania. We’re moving production of some drugs from India to Romania for Europe and the ex-Soviet space (…)” Damian said.